Aptahem AB (publ) announces today that the company has received patent protection in USA for patent family 2 from the United States Patent and Trademark Office (USPTO). The approval follows the previous preliminary approval from USPTO which was communicated...
Read MoreAptahem AB (publ) announces today that the European Patent Office (EPO) has approved the EU patent application EP 18783424.7 entitled A nucleic acid molecule with anti-inflammatory and anti-coagulant and organ-protective properties. The approval follows the previous provisional approval by...
Read MoreAptahem AB (publ) announces today that the GLP (Good Laboratory Practice) toxicology and safety studies preliminary show positive results. The studies are the final part of the preclinical program before an application to start clinical studies can be filed....
Read MoreBioStock published an article on 12 July 2021 about Aptahem, which can be read in full below. During 2021, sepsis company Aptahem has taken several steps to prepare for its first clinical evaluation of its leading drug candidate Apta-1....
Read MoreAptahem AB (publ) announces today that the company has received information that the European Patent Office (EPO) has issued an Intention to Grant of the EU patent application EP 18783424.7 entitled A nucleic acid molecule with anti-inflammatory and anti-coagulant...
Read MoreBioStock published an article on 1 July 2021 about Aptahem, which can be read in full below. Since 2019, Aptahem has collaborated with the Cardiovascular Research Centre (CVRC) at Örebro University to better understand certain mechanisms behind Apta-1’s effect....
Read MoreAptahem AB (publ) announces today that the company has received information that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance fo the US patent application 16/652,926 entitled A nucleic acid molecule with anti-inflammatory...
Read MoreAptahem AB (publ) announce today that the collaboration with the Cardiovascular Research Centre (CVRC) at Örebro University to map the details behind Apta-1’s effects with the support from the Knowledge Foundation’s Prospect Call now has generated results that clarify...
Read MoreBioStock published an article on 26 May 2021 about Aptahem, which can be read in full below. The most anticipated milestone for sepsis company Aptahem is initiating first-in-human trials with candidate Apta-1, which is planned for next year. BioStock...
Read MoreBioStock published an article on 5 May 2021 about Aptahem, which can be read in full below. Biotechnology company Aptahem, which is developing the preclinical drug candidate Apta-1 for the treatment of sepsis, recently announced that it has suspended...
Read More